Found 9 Hepatitis trials
A listing of Hepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
For subjects age 18 years and older who are at an increased risk for HCC and for whom HCC surveillance is appropriate, including subjects with cirrhosis or non-cirrhotic subjects with Hepatitis B. Approximately 3,000 subjects are expected to be enrolled, comprised of approximately 2,222 ultrasound surveillance subjects and 778 subjects …
Long Acting Therapy to Improve Treatment SUccess in Daily LifE (The LATITUDE Study)
Phase 3
This study is meant for patients who have difficulty taking their HIV meds as prescribed. One goal of the study is to test the effectiveness of long-acting antiretroviral therapy (ART) -- a once-a-month injection that replaces daily ART pills. You will also receive compensation for participating in this study, with …
A5394: Safety Tolerability and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV
A5394 is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
Intercept 787-201
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis.
A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients
Phase 2
The THINKER-NEXT research study is being done to determine whether it is safe to give a kidney transplant from a donor with hepatitis C to a patient without hepatitis C. The recipient will then be given a drug called Epclusa for 12 weeks to treat hepatitis C. Patients who are …
Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors
Phase 2
Since 2006, there has been a 50% increase in the number of adults added to the heart transplant waitlist in the US. Yet the persistent organ donor shortage has led to only a 25% increase in the number of transplants, and a 25% increase in the number of patients removed …
“Real World” Administration of Zepatier (Grazoprevir plus Elbasvir in Chronic Hemodialysis Patients with Hepatitis C Infection. Strategies for Identification of Candidate Hemodialysis Patients, Obtainment of Insurance Approval, Treatment Guidelines, and Laboratory and Clinical Monitoring During Therapy Directed to Nephrologists
The purpose of this study is to learn how to dialysis doctors can treat dialysis patients infected with Hepatitis C themselves. Hepatitis C infection is common in hemodialysis patients. There are new medications, such as Zepatier, which can cure hepatitis C in > 95% of patients. Zepatier is particularly good …
KZR-616-208
To evaluate the safety and tolerability of zetomipzomib in patients with autoimmune hepatitis (AIH) and to evaluate the efficacy of the drug in addition to standard-of-care in patients with AIH who have failed standard-of-care treatment. Target population = 3 subjects. Subjects will be randomized to either treatment or control and …
TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum
Phase 1
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell …
